Pulmonary hypertension trials: how can we do better?

Area of Science:

• Cardiology
• Clinical Research
• Pulmonary Medicine

Background:

• Clinical trials for pulmonary hypertension (PH) in Western countries are increasingly difficult and expensive.
• Challenges include small patient populations, making recruitment hard, and international recruitment adding variability.
• Current endpoints, like the 6-minute walk distance, may not fully reflect PH pathogenesis, and event-driven designs require large patient numbers and long durations.

Purpose of the Study:

• To discuss the challenges in conducting clinical trials for pulmonary hypertension.
• To explore the limitations of current clinical trial endpoints and designs.
• To suggest ways to facilitate the evaluation of new therapies for PH.

Main Methods:

• Review of challenges in clinical trial conduct for pulmonary hypertension.
• Analysis of current and proposed endpoints for PH trials.
• Discussion of regulatory and design considerations for PH clinical trials.

Main Results:

• Limited patient populations and the lack of ideal endpoints are significant hurdles in PH clinical trials.
• Event-driven trial designs, while informative, necessitate large patient cohorts and extended study periods.
• Functional or hemodynamic endpoints remain valuable for testing novel PH agents.

Conclusions:

• Facilitating PH clinical trials requires addressing recruitment difficulties and endpoint limitations.
• Streamlining trial designs and regulatory oversight can accelerate the development of new PH treatments.
• Continued research into optimal endpoints and trial methodologies is essential for advancing PH care.